Intestinal Failure-Associated Liver Disease and Eicosapentaenoic Acid/Arachidonic Acid Ratio

Wataru Miura, Nobuhiko Nagano, Ryota Kato, Aya Okahashi, Kayo Yoshikawa, Kensuke Ohashi, Tsugumichi Koshinaga, Ichiro Morioka

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Intestinal failure-associated liver disease (IFALD) is a fatal complication of short bowel syndrome managed with parenteral nutrition. A clinical cohort study reported the usefulness of parenteral administration of fish-derived omega-3 fatty acids in improving IFALD; however, no biomarker has been developed as yet. The authors report the case of a preterm infant with IFALD complicated by extensive short bowel syndrome. Intravenous administration of omega-3 fatty acids were introduced using Omegaven®at the age of 4 mo for IFALD. The IFALD improved with an increase in Eicosapentaenoic acid (EPA)/ Arachidonic acid (AA) ratio (from 0.08 to 1.99) 7 d after the intravenous treatment. It is important to administer omega-3 fatty acids intravenously at an early stage for IFALD associated with extensive short bowel syndrome. A low EPA/AA ratio may be a serum marker of disease activity in IFALD.

Original languageEnglish
Pages (from-to)548-550
Number of pages3
JournalIndian Journal of Pediatrics
Issue number6
Publication statusPublished - 1 Jun 2019


  • Eicosapentaenoic acid/Arachidonic acid ratio
  • Intestinal failure-associated liver disease
  • Intravenous administration
  • Omega-3 fatty acids
  • Severe short bowel syndrome


Dive into the research topics of 'Intestinal Failure-Associated Liver Disease and Eicosapentaenoic Acid/Arachidonic Acid Ratio'. Together they form a unique fingerprint.

Cite this